8-KMaterial AgreementsExhibits & Filings

AMGEN INC 8-K Report, Material Agreement (Feb 21, 2020)

Filed February 21, 2020For Securities:AMGN

Summary

Amgen Inc. (AMGN) announced on February 21, 2020, the successful issuance and sale of a significant aggregate principal amount of senior notes across multiple maturities, totaling approximately $4.95 billion in net proceeds. This debt offering includes notes due in 2025, 2027, 2030, 2040, and 2050, with coupon rates ranging from 1.900% to 3.375%. The substantial capital raised indicates Amgen's strategic financial management and potential for future investments in research, development, or acquisitions. The net proceeds, approximately $4.956 billion after fees, will bolster Amgen's liquidity and financial flexibility. The notes are registered under a previously filed Form S-3 registration statement and were issued under an existing indenture with amendments formalized by an officer's certificate. This offering diversifies Amgen's debt maturity profile and secures long-term funding at attractive interest rates, reflecting favorable market conditions and the company's creditworthiness.

Key Highlights

  • 1Amgen successfully issued $4.95 billion in aggregate principal amount of senior notes on February 21, 2020.
  • 2The offering includes notes with maturities in 2025, 2027, 2030, 2040, and 2050.
  • 3Interest rates on the notes range from a low of 1.900% for the 2025 notes to 3.375% for the 2050 notes.
  • 4The net proceeds from the offering were approximately $4.956 billion, after deducting discounts and expenses.
  • 5The notes are senior unsecured obligations, ranking equally with other existing and future senior unsecured indebtedness.
  • 6A 'change in control' triggering event allows noteholders to require Amgen to purchase their notes at 101% of the principal amount plus accrued interest.
  • 7The offering was made under an effective Form S-3 registration statement filed on February 10, 2020.

Frequently Asked Questions

This 8-K filing primarily announces Amgen's entry into a material definitive agreement related to the issuance and sale of $4.95 billion in aggregate principal amount of its senior notes.

Amgen raised approximately $4.956 billion in net proceeds from the offering. The filing does not specify the exact use of these funds, but such proceeds are typically used for general corporate purposes, including funding operations, research and development, potential acquisitions, or refinancing existing debt.

The notes have varying maturities (2025, 2027, 2030, 2040, 2050) and coupon rates (1.900%, 2.200%, 2.450%, 3.150%, 3.375%). Interest is payable semi-annually. In case of a change in control, noteholders have the option to sell their notes back to Amgen at 101% of the principal amount plus accrued interest.

The new senior notes rank equally with Amgen's other existing and future senior unsecured indebtedness. They are senior to any subordinated debt and effectively subordinated to obligations of Amgen's subsidiaries, as well as any secured debt to the extent of the collateral.